ARID1A mutations, along with other members of the ARID family (ARID1B, ARID2), have been associated with positive predictive value for ICI therapy in multiple cancer types.21 However, validation of this approach in GBM and astrocytoma has been limited. The gene discussed is ARID2; the disease is astrocytoma (excluding glioblastoma).